Adults with asthma are at increased risk for pneumococcal disease, yet according to a new Centers for Disease Control and Prevention (CDC) study published today in the American Journal of Preventive Medicine, just 54 percent of adults with work-related asthma-asthma triggered by an exposure at work-have been vaccinated against the infection. CDC recommends all adults 19 through 64 years old with asthma get the pneumococcal polysaccharide vaccine.
CDC’s National Institute for Occupational Safety and Health (NIOSH) researchers found that adults with work-related asthma were more likely to have reported receiving a pneumococcal vaccine than adults with non-work-related asthma - 54 percent compared with 35 percent, respectively. Among adults with work-related asthma, pneumococcal vaccine coverage was lowest among Hispanics (36 percent), those without health insurance (39 percent), and adults ages 18 to 44 years (42 percent).
“People with work-related asthma are particularly vulnerable to pneumococcal pneumonia,” said NIOSH director John Howard, MD. “Vaccination is the best way to prevent pneumococcal disease, including pneumonia, and CDC recommends that all adults with asthma, whether work-related or not, get the pneumococcal polysaccharide vaccine.”
The study analyzed data from the 2012-2013 Behavioral Risk Factor Surveillance System (BRFSS), a state-based telephone survey, which includes an optional follow-up survey that collects detailed information on asthma. Nearly 10,000 adults ages 18-64 years with asthma from 29 states who have ever held a job, representing an estimated 12 million people, were included in the analysis. Of the adults with asthma in the study, researchers estimated 15 percent had work-related asthma.
The CDC estimates that about 900,000 Americans get pneumococcal pneumonia each year and about 5 percent to 7 percent die from it. Adults with asthma who get pneumococcal pneumonia are at risk for additional complications including asthma exacerbation and invasive pneumococcal disease. The Advisory Committee on Immunization Practices recommends a pneumococcal polysaccharide vaccination for all adults 19 through 64 years old with asthma.
“Our study found that the vaccination coverage for pneumococcal disease among adults who have ever worked and have asthma falls short of achieving the coverage public health experts recommend,” said Katelynn Dodd, MPH, lead author and an epidemiologist in the Respiratory Health Division, NIOSH. “To increase the number of adults with asthma who are vaccinated against pneumococcal disease, we recommend that healthcare providers verify if their patients who have asthma have received a pneumococcal vaccine and offer the vaccine to those not vaccinated.”
Pneumococcal disease is an infection caused by Streptococcus pneumoniae, which can cause many types of illnesses including ear infections, meningitis, and pneumonia. Vaccination is the safest, most effective way to protect yourself from getting pneumococcal disease. Pneumococcal vaccines help protect against some of the more than 90 types of pneumococcal bacteria.
Source: CDC
The Sterile Processing Conference Survival Guide: How to Make the Most of Your Next Event
March 25th 2025From expert speakers to cutting-edge tools, sterile processing conferences, like the 2025 HSPA Annual Conference and the SoCal SPA's Spring Conference, offer unmatched opportunities to grow your skills, expand your network, and strengthen your department's infection prevention game.
Redefining Material Compatibility in Sterilization: Insights From AAMI TIR17:2024
March 24th 2025AAMI TIR17:2024 provides updated, evidence-based guidance on material compatibility with sterilization modalities. It offers essential insights for medical device design and ensures safety without compromising functionality.
Unraveling a Candida auris Outbreak: Infection Control Challenges in a Burn ICU
March 19th 2025A Candida auris outbreak in a burn intensive care unit (BICU) in Illinois has highlighted the persistent challenges of infection control in high-risk health care settings. Despite rigorous containment efforts, this multidrug-resistant fungal pathogen continued to spread, underscoring the need for enhanced prevention strategies, environmental monitoring, and genomic surveillance.
The Sterile Processing Conference Survival Guide: How to Make the Most of Your Next Event
March 25th 2025From expert speakers to cutting-edge tools, sterile processing conferences, like the 2025 HSPA Annual Conference and the SoCal SPA's Spring Conference, offer unmatched opportunities to grow your skills, expand your network, and strengthen your department's infection prevention game.
Redefining Material Compatibility in Sterilization: Insights From AAMI TIR17:2024
March 24th 2025AAMI TIR17:2024 provides updated, evidence-based guidance on material compatibility with sterilization modalities. It offers essential insights for medical device design and ensures safety without compromising functionality.
Unraveling a Candida auris Outbreak: Infection Control Challenges in a Burn ICU
March 19th 2025A Candida auris outbreak in a burn intensive care unit (BICU) in Illinois has highlighted the persistent challenges of infection control in high-risk health care settings. Despite rigorous containment efforts, this multidrug-resistant fungal pathogen continued to spread, underscoring the need for enhanced prevention strategies, environmental monitoring, and genomic surveillance.
2 Commerce Drive
Cranbury, NJ 08512